Loading…
ADMA Biologics, Inc. is projected to rise to $10.16 by 2027, a +17% move from its current price of $8.67. ADMA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $8.53 | $8.67 | $8.82 | +0.04% |
| Aug 2 | $8.47 | $8.68 | $8.89 | +0.07% |
| Aug 3 | $8.42 | $8.68 | $8.94 | +0.11% |
| Aug 4 | $8.39 | $8.68 | $8.99 | +0.15% |
| Aug 5 | $8.36 | $8.69 | $9.03 | +0.19% |
| Aug 6 | $8.33 | $8.69 | $9.06 | +0.22% |
| Aug 7 | $8.31 | $8.69 | $9.10 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.31 | $8.69 | $9.10 | +0.26% |
| Week 2 | $8.17 | $8.72 | $9.30 | +0.52% |
| Week 3 | $8.07 | $8.74 | $9.46 | +0.78% |
| Week 4 | $8.00 | $8.76 | $9.60 | +1.04% |
| Week 5 | $7.93 | $8.78 | $9.73 | +1.31% |
| Week 6 | $7.88 | $8.81 | $9.85 | +1.57% |
| Week 7 | $7.83 | $8.83 | $9.96 | +1.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company operates through two segments, ADMA BioManufacturing and Plasma Collection Centers. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Biologics, Inc. (ADMA) is a healthcare stock with a current price of $8.38. It has a market capitalization of $1.94B and is ranked 1978 in market cap terms.
The price outlook from the provided forecast shows a neutral near term in 2026, with an average price of $8.38 and a range from $7.60 to $11.07. The sentiment for 2026 is NEUTRAL. Longer term, the forecast envisions higher averages and stronger returns, with 2040 and 2050 showing substantial upside (average prices of $21.67 and $36.75 respectively, and ROIs of 158.6% and 338.6%).
A major floor 12.3% below — a decisive break under it would weaken the trend.
The nearest floor, 4.6% below — buyers have tended to step in here.
The nearest ceiling, 6.9% above — a clean break opens room to run.
A major ceiling 56.7% above — clearing it would confirm fresh momentum.
Key ADMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.58 | Buy | $8.63 | Buy |
| MA 10 | $8.57 | Buy | $8.63 | Buy |
| MA 20 | $8.79 | Sell | $8.66 | Buy |
| MA 50 | $8.49 | Buy | $8.93 | Sell |
| MA 100 | $9.74 | Sell | $10.15 | Sell |
| MA 200 | $13.37 | Sell | $12.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.90 | Neutral |
| Stoch RSI (14) | 70.28 | Neutral |
| CCI (20) | -35.42 | Neutral |
| Williams %R (14) | -42.86 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -2.25 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 57.14 | Neutral |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 49.79 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 8.74 | Sell |
| ADX (14) | 11.40 | Neutral |
| ATR (14) | 0.14 | Info |
The near-term technical picture is bearish. The RSI(14) is 40, indicating more room to move before overbought conditions. The 50-day simple moving average is $8.47, while the 200-day simple moving average is $13.55.
Support stands at $8.12 and resistance at $9.27, framing a near-term trading range around the current level. The 30-day price range spans from $7.45 to $9.42, highlighting contained downside risk within this window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.60 | $8.67 | $11.38 | 0% | Neutral | |
| $8.33 | $10.16 | $12.95 | +17% | Neutral | |
| $8.20 | $10.19 | $13.35 | +18% | Neutral | |
| $8.62 | $10.88 | $14.56 | +26% | Bullish | |
| $8.83 | $11.30 | $15.39 | +30% | Bullish | |
| $9.12 | $11.81 | $16.33 | +36% | Bullish | |
| $10.08 | $13.21 | $18.53 | +52% | Bullish | |
| $11.43 | $15.13 | $21.51 | +75% | Bullish | |
| $12.44 | $16.63 | $23.92 | +92% | Bullish | |
| $12.33 | $16.64 | $24.21 | +92% | Bullish | |
| $16.98 | $23.91 | $36.45 | +176% | Bullish | |
| $26.86 | $40.55 | $66.28 | +368% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.60 | $8.67 | $10.09 | +0.00% |
| August 2026 | $7.43 | $8.67 | $10.30 | -0.05% |
| September 2026 | $7.65 | $8.97 | $10.76 | +3.49% |
| October 2026 | $7.86 | $9.26 | $11.19 | +3.25% |
| November 2026 | $7.82 | $9.25 | $11.24 | -0.13% |
| December 2026 | $7.85 | $9.31 | $11.38 | +0.72% |
Click any year to see its month-by-month ADMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADMA could reach as high as $11.38, with a base case around $8.67 and support toward $7.60 — roughly 0% from $8.67. Price action looks broadly range-bound.
Expect ADMA to range from $8.33 to $12.95 through 2027. The $10.16 average target implies a +17% move from current prices. That is up +17% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ADMA price prediction for 2028 points to an average of $10.19 (low $8.20, high $13.35) — a potential gain of +18% on today's $8.67. Price action looks broadly range-bound.
In 2029, ADMA is projected to trade between $8.62 and $14.56, averaging $10.88 — a potential gain of +26% from today's $8.67. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
ADMA Biologics, Inc.'s 2030 outlook centres on $11.30, within a $8.83 to $15.39 range. That is up +4% on the projected 2029 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2031, ADMA could reach as high as $16.33, with a base case around $11.81 and support toward $9.12 — roughly +36% from $8.67. Buyers look set to stay in control over this stretch.
Expect ADMA to range from $10.08 to $18.53 through 2032. The $13.21 average target implies a +52% move from current prices. That is up +12% on the projected 2031 average. Momentum favours further upside here.
The ADMA price prediction for 2033 points to an average of $15.13 (low $11.43, high $21.51) — a potential gain of +75% on today's $8.67. Buyers look set to stay in control over this stretch.
In 2034, ADMA is projected to trade between $12.44 and $23.92, averaging $16.63 — a potential gain of +92% from today's $8.67. That is up +10% on the projected 2033 average. Momentum favours further upside here.
ADMA Biologics, Inc.'s 2035 outlook centres on $16.64, within a $12.33 to $24.21 range. That is up 0% on the projected 2034 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ADMA could reach as high as $36.45, with a base case around $23.91 and support toward $16.98 — roughly +176% from $8.67. Momentum favours further upside here.
Expect ADMA to range from $26.86 to $66.28 through 2050. The $40.55 average target implies a +368% move from current prices. That is up +70% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADMA today (≈ 115.340254 ADMA) could be worth
$4,676.9
+$3,676.9 (+368%) by 2050 · US Dollar
Based on the average projected ADMA price of $40.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADMAwould be worth at today's price.
$1,000 invested in ADMA on Jul 30, 2025 (≈ 53.792361 ADMA) would be worth
$466.38
-$533.62 (-53.4%) today · 0.47× · US Dollar
Based on a ADMA entry price of $18.59 vs. today's $8.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.37 | $1,035.84 | +3.6% |
| 1 month ago | $8.37 | $1,035.84 | +3.6% |
| 3 months ago | $10.52 | $824.14 | -17.6% |
| 6 months ago | $17.3 | $501.16 | -49.9% |
| 1 year ago | $18.59 | $466.38 | -53.4% |
| All time (5.0y) ago | $1.59 | $5,452.83 | +445.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADMA forecast.
Our base-case forecast reaches $17.00 around 2040.
Implied market cap at $17.00: $3.94B
The multi-year forecast paints a bullish arc after a neutral start, with notable upside in later years. In 2029 the average price is $10.41 with a max of $13.93 and a ROI of 24.2%, followed by 2030 with an average of $10.69 and a max of $14.56 and a ROI of 27.5%.
The growth continues into 2031–2035, where forecasts show 2031 average $10.94 (ROI 30.6%), 2032 average $12.36 (ROI 47.5%), 2033 average $14.07 (ROI 67.9%), 2034 average $15.31 (ROI 82.7%), and 2035 average $15.44 (ROI 84.3%). By 2040, the average is projected at $21.67 (ROI 158.6%), and by 2050 the average reaches $36.75 (ROI 338.6%).
These figures are estimates, not guarantees, and reflect the anticipated path of prices and sentiment across the forecast horizon.
Tap a question to reveal the answer.
Average price is $10.69, minimum $8.35, maximum $14.56, with a ROI of 27.5% and bullish sentiment.
The forecast shows neutral sentiment in 2026 and 2027–2028, then bullish from 2029 onward, with ROIs including 24.2% (2029), 27.5% (2030), and up to 338.6% by 2050.
Yes. The 2035 forecast has an average of $15.44 and a maximum of $22.47, indicating a potential high near that level.
Current price is $8.38 and market cap is $1.94B.
The 30-day range is from $7.45 to $9.42, with support at $8.12 and resistance at $9.27.
ADMA Biologics, Inc. Community Discussion
0Share your ADMA Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.